Table 3.
Baseline subject characteristics for acute MI subgroup analysis
| Variable | Type 1 MI (N = 22) | Type 2 MI (N = 12) | p value |
|---|---|---|---|
| Age (mean ± SD) years | 58.7 ± 15.1 | 56.3 ± 16.6 | 0.67 |
| Males (%) | 72.7 | 41.7 | 0.14 |
| Caucasian race (%) | 86.4 | 66.7 | 0.21 |
| Current smoker (%) | 45.5 | 50.0 | 1.00 |
| Currently consumes alcohol (%) | 36.4 | 33.3 | 0.78 |
| History of dyslipidemia (%) | 54.5 | 33.3 | 0.30 |
| History of diabetes mellitus (%) | 9.1 | 0.0 | 0.53 |
| History of hypertension (%) | 45.5 | 75.0 | 0.19 |
| History of atherosclerosis (%) (MI, CAD, PCI, CABG) | 40.9 | 33.3 | 0.73 |
| History of congestive heart failure (%) | 0.0 | 8.3 | 0.35 |
| History of chronic renal failure (%) | 4.5 | 8.3 | 0.43 |
| History of stroke (%) | 4.5 | 25.0 | 0.12 |
| HR at time of presentation (mean ± SD) | 87.4 ± 27.2 | 88.3 ± 27.5 | 0.93 |
| MAP at time of presentation (mean ± SD) | 104.1 ± 19.8 | 95.4 ± 26.9 | 0.29 |
| BMI at time of presentation (mean ± SD) | 27.5 ± 7.4 | 27.8 ± 6.7 | 0.90 |
| Time (hours) elapsed presentation to angiogram (median ± IQR, range) | 1.0 ± 1.0, 13.0 | 18.0 ± 9.5, 30.0 | < 0.0001b |
| Baseline Troponin (mean ± SD, range) mg/dL | 7.8 ± 14.9, 55.3 | 2.4 ± 2.9, 9.8 | 0.76b |
| Peak troponin (mean ± SD, range) | 51.6 ± 41.2, 145.7 | 11.6 ± 22.0, 68.2 | 0.0002b |
| Glucose at baseline (mean ± SD, range) | 166.5 ± 58.9, 246 | 118.0 ± 47.7, 182 | 0.01a |
| Creatinine at baseline (mean ± SD, range) | 0.98 ± 0.43, 2.38 | 1.21 ± 1.07, 3.80 | 0.50a |
| ST Elevation on EKG at baseline | 100.0 | 25.0 | < 0.0001 |
| At least one vessel with ≥50 % coronary stenosis on enrollment angiogram | 100.0 | 0.0 | < 0.0001 |
| Aspirin use at time of enrollment (%) | 86.4 | 91.7 | 1.00 |
| P2Y12 Inhibitors use at enrollment (%) | 45.5 | 50.0 | 1.00 |
MI myocardial infarction, CAD coronary artery disease, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, HR heart rate, SBP systolic blood pressure, DBP diastolic blood pressure, MAP mean arterial pressure, BMI body mass index, ACE-I angiotensin converting enzyme inhibitor
a
Welch’s t-test
b
Wilcoxon rank-sum test